Higgitt A, Fonagy P, Lader M
Department of Psychiatry, St Mary's Hospital, London.
Psychol Med Monogr Suppl. 1988;13:1-55. doi: 10.1017/s0264180100000412.
Dependence on benzodiazepines following continued use is by now a well-documented clinical phenomenon. Benzodiazepines differ in their dependence potential. The present studies were aimed at examining the possibility that differential rates of tolerance development might account for differences in dependence risk. Four studies are reported. The first three studies concerned normal subjects. The development of tolerance over a fifteen day period was demonstrated for three different benzodiazepines (ketazolam, lorazepam and triazolam) using two paradigms. Tolerance in terms of a reduction in effectiveness of a repeated given dose was most notable for the benzodiazepine with a medium elimination half-life (lorazepam) for physiological, behavioural and subjective measures. In the case of the drug with the longest elimination half-life (ketazolam) reduction in effectiveness could only be assumed to be occurring if account was taken of the steady increase in plasma concentrations of active metabolites. For this drug it seemed that the physiological measures were those most likely to demonstrate the development of tolerance. Although triazolam showed few significant drug effects on this paradigm (testing being 12 hours after ingestion of this short half-life benzodiazepine), tolerance was seen to develop on some subjective measures. Using an alternative method of testing tolerance, assessing responses to a diazepam challenge dose, a high degree of tolerance on two-thirds of the measures was observed in subjects when pretreated with the benzodiazepine with the most marked accumulation of active metabolites (ketazolam). The other two drugs also led to tolerance development on a range of measures; this was more marked for lorazepam than triazolam. Blunting of the growth hormone response to diazepam was the most sensitive and reliable method of detecting tolerance to the benzodiazepines. Symptoms on discontinuation of the two weeks' intake of the benzodiazepines were marked for all the drugs but unrelated to either the tolerance induced or the elimination half-life of the particular drug. A further clinical study revealed that tolerance persisted in a group of long-term benzodiazepine users for between four months and two years following complete abstinence from the drug. These patients appeared to be less affected by diazepam in terms of its commonly observed subjective effects, regardless of their original medication. These ex-long-term users of benzodiazepines were, however, more likely to manifest two specific types of effects--immediate 'symptom' reduction and exacerbation of 'withdrawal symptoms' over the subsequent week.(ABSTRACT TRUNCATED AT 400 WORDS)
持续使用苯二氮䓬类药物后产生依赖性,如今已是一个有充分文献记载的临床现象。不同苯二氮䓬类药物的成瘾潜力有所不同。目前的研究旨在探讨耐受性发展速率差异是否可能是导致成瘾风险差异的原因。本文报告了四项研究。前三项研究针对正常受试者。采用两种模式,对三种不同的苯二氮䓬类药物(氯氮卓、劳拉西泮和三唑仑)在15天内耐受性的发展情况进行了研究。对于生理、行为和主观测量指标,具有中等消除半衰期的苯二氮䓬类药物(劳拉西泮),重复给予一定剂量后效果降低方面的耐受性最为显著。对于消除半衰期最长的药物(氯氮卓),只有考虑到活性代谢物血浆浓度的持续升高,才能假定其效果有所降低。对于这种药物,生理测量指标似乎最有可能显示出耐受性的发展。尽管三唑仑在该模式下几乎未显示出显著的药物效应(在摄入这种半衰期短的苯二氮䓬类药物12小时后进行测试),但在一些主观测量指标上仍观察到耐受性的发展。使用另一种测试耐受性的方法,评估对安定激发剂量的反应,在预先用活性代谢物积累最为显著的苯二氮䓬类药物(氯氮卓)进行预处理的受试者中,三分之二的测量指标上观察到了高度耐受性。其他两种药物在一系列测量指标上也导致了耐受性的发展;劳拉西泮比三唑仑更为明显。对安定的生长激素反应减弱是检测对苯二氮䓬类药物耐受性最敏感和可靠的方法。所有药物在停用两周的苯二氮䓬类药物后症状都很明显,但与所诱导的耐受性或特定药物的消除半衰期均无关。另一项临床研究表明,一组长期使用苯二氮䓬类药物的患者在完全停药后,耐受性持续了4个月至2年。这些患者在安定常见的主观效应方面似乎受影响较小,无论他们原来使用的药物是什么。然而,这些曾经长期使用苯二氮䓬类药物的患者更有可能表现出两种特定类型的效应——立即“症状”减轻以及在随后一周内“戒断症状”加重。(摘要截选至400字)